News from oxthera ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

23 Aug, 2019, 09:00 BST OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes

OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced...


27 Jun, 2019, 09:00 BST Oxthera Presents Continuous Strong Data From an Interim Analysis of Its Phase 2 Study With Oxabact in Primary Hyperoxaluria

OxThera AB, a privately-held biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria (PH), today...


20 Jun, 2019, 09:00 BST OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria

OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first...


15 Nov, 2018, 08:30 GMT OxThera AB is Being Granted US Patent for Oxalobacter Secretagogues

OxThera AB, a privately-held Stockholm-based biopharmaceutical company, today announced a granted US patent on Oxalobacter formigenes secretagogues....


31 Oct, 2018, 12:42 GMT OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD

OxThera AB, a Stockholm-based privately-held biopharmaceutical company and leader in the field of microbiome derived biotherapeutics, today announced ...


07 Sep, 2018, 10:44 BST Hugo Petit Appointed CFO of OxThera

OxThera AB, a Stockholm-based privately-held rare disease company today announced the appointment of Hugo Petit as its new Chief Financial Officer....


10 Jul, 2018, 18:01 BST OxThera Updates on Phase 3 Study With Oxabact® in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that the Phase 3 study with Oxabact® in Primary Hyperoxaluria ...


12 Jun, 2018, 16:57 BST OxThera Announces the Appointment of Dr Alain Munoz to its Board of Directors

OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary...


14 Mar, 2018, 19:54 GMT OxThera Announces the Randomization of the First Patient Into its Phase III EPHEX Study With Oxabact

OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary...


08 Nov, 2017, 19:01 GMT OxThera Strengthens Patent Portfolio for Treatment of Hyperoxaluria

OxThera AB announced today that it has recently been granted two new US patents, three new European patents and patents in Canada, China, Hong-Kong,...


13 Oct, 2017, 07:54 BST Dr. Bastian Dehmel Appointed CMO of OxThera

OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr. Bastian Dehmel as their new Chief...


05 Jul, 2017, 08:30 BST Matthew Gantz Appointed CEO of OxThera

OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Matthew Gantz as their new CEO. He succeeds ...


23 Sep, 2014, 08:30 BST Oxabact® Granted EMA Orphan Drug Designation for Treatment of SBS

OxThera AB announced today that its product Oxabact® has been granted an Orphan Drug Designation in the European Union for treatment of Short Bowel...